Fecal Microbiota Transplantation (FMT): PRIM-DJ2727

NCT ID: NCT03786900

Last Updated: 2023-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor.

Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call. A screening list for donors will be provided to make sure that the list fits the requestor's requirements. A basic fee will be requested to recover the cost of making the product. After an agreement is made, a contract will be signed between the 2 parties. A week before the treatment, requestors will contact the study team for possible FMT product delivery. Delivery method will be confirmed for delivery by personnel (within 10 minutes driving distance) or by using FedEx services. Each delivered product will have an approved delivery form signed and dated by both the person who prepared the delivery and the person who received the package.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Clostridium Difficile Infection Multidrug-resistant Klebsiella Pneumoniae Urinary Tract Infection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Herbert DuPont, MD

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Herbert DuPont, MD

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Herbert DuPont, MD

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center, Houston

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Herbert L DuPont, MD

Role: CONTACT

713 500 9366

Zhi-Dong Jiang, MD, DrPH

Role: CONTACT

713-500-9371

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HSC-SPH-15-0991

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fecal Microbiota Transplant for Primary CDI
NCT03795233 TERMINATED PHASE1/PHASE2
Fecal Microbiota Transplantation (FMT) for MDRO UTI
NCT03367910 COMPLETED PHASE1/PHASE2
MTC Versus FMT in for RCDI
NCT05911997 RECRUITING PHASE1
Freeze-dried, Capsulized FMT for RCDI
NCT02399618 UNKNOWN PHASE1
Early FMT for C.Difficile
NCT02465463 COMPLETED PHASE1/PHASE2
FMT in Uncomplicated Diverticulitis
NCT05373784 ACTIVE_NOT_RECRUITING EARLY_PHASE1